amifostine anhydrous has been researched along with Leukemia, Myeloid in 5 studies
Amifostine: A phosphorothioate proposed as a radiation-protective agent. It causes splenic vasodilation and may block autonomic ganglia.
amifostine : An organic thiophosphate that is the S-phospho derivative of 2-[(3-aminopropyl)amino]ethanethiol. A prodrug for the free thiol, WR-1065, which is used as a cytoprotectant in cancer chemotherapy and radiotherapy.
Leukemia, Myeloid: Form of leukemia characterized by an uncontrolled proliferation of the myeloid lineage and their precursors (MYELOID PROGENITOR CELLS) in the bone marrow and other sites.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Five patients were treated at an idarubicin dose of 18 mg/m2/day x 3, three of whom developed grade 3 diarrhea or mucositis." | 5.10 | A phase I study of idarubicin dose escalation with amisfostine and high-dose cytarabine in patients with relapsed acute myelogenous leukemia and myelodysplastic syndromes. ( Cortes, J; Davis, J; Estey, E; Faderl, S; Garcia-Manero, G; Giles, F; Kantarjian, HM; O'Brien, S; Thomas, D, 2002) |
| "Thirty-five patients (20 with non-Hodgkin lymphoma, 12 with Hodgkin disease, and 3 with acute myelogenous leukemia) who underwent autologous stem cell transplantation were conditioned with total body irradiation 2 Gy twice daily on days -8 through -6; cyclophosphamide 6 g/m(2), etoposide 1." | 2.71 | Cytoprotection by amifostine during autologous stem cell transplantation for advanced refractory hematologic malignancies. ( Gabriel, DA; Harvey, D; Kirby, SL; Krasnov, C; Moore, DT; Serody, JS; Shea, TC, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Garcia-Manero, G | 1 |
| Faderl, S | 1 |
| Giles, F | 1 |
| Thomas, D | 1 |
| Cortes, J | 1 |
| O'Brien, S | 1 |
| Davis, J | 1 |
| Kantarjian, HM | 1 |
| Estey, E | 1 |
| Acosta, JC | 1 |
| Richard, C | 1 |
| Delgado, MD | 1 |
| Horita, M | 1 |
| Rizzo, MG | 1 |
| Fernández-Luna, JL | 1 |
| León, J | 1 |
| Gabriel, DA | 1 |
| Shea, TC | 1 |
| Serody, JS | 1 |
| Moore, DT | 1 |
| Kirby, SL | 1 |
| Harvey, D | 1 |
| Krasnov, C | 1 |
| List, AF | 1 |
| Gerner, EW | 1 |
| Perambakam, S | 1 |
| Li, B | 1 |
| Preisler, H | 1 |
2 trials available for amifostine anhydrous and Leukemia, Myeloid
| Article | Year |
|---|---|
A phase I study of idarubicin dose escalation with amisfostine and high-dose cytarabine in patients with relapsed acute myelogenous leukemia and myelodysplastic syndromes.
Topics: Adult; Amifostine; Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy P | 2002 |
Cytoprotection by amifostine during autologous stem cell transplantation for advanced refractory hematologic malignancies.
Topics: Acute Disease; Adolescent; Adult; Amifostine; Cytoprotection; Female; Graft Survival; Hematopoietic | 2005 |
3 other studies available for amifostine anhydrous and Leukemia, Myeloid
| Article | Year |
|---|---|
Amifostine impairs p53-mediated apoptosis of human myeloid leukemia cells.
Topics: Amifostine; Annexin A5; Apoptosis; bcl-X Protein; Blotting, Northern; Caspases; Fluorescent Antibody | 2003 |
Amifostine: a tonic or toxin to myeloid progenitors.
Topics: Amifostine; Animals; Antineoplastic Agents; Apoptosis; Cell Survival; Humans; Leukemia, Myeloid; Mer | 2000 |
Quantitation of interferon regulatory factor transcripts in patients with acute myeloid leukemia.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Amifostine; Bone Marrow Cells; DNA-Binding Proteins; | 2001 |